Marc Ditmarsch
Overview
Explore the profile of Marc Ditmarsch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmidt A, Davidson M, Ditmarsch M, Kastelein J, Finan C
Alzheimers Res Ther
. 2024 Dec;
16(1):276.
PMID: 39731193
No abstract available.
2.
Nicholls S, Nelson A, Kastelein J, Ditmarsch M, Hsieh A, Johnson J, et al.
Pharmacol Res Perspect
. 2024 Oct;
12(6):e70010.
PMID: 39425271
Anacetrapib, a cholesteryl ester transfer protein (CETP) inhibitor previously under development, exhibited an usually extended terminal half-life and large food effect and accumulated in adipose tissue. Other CETP inhibitors have...
3.
Schmidt A, Davidson M, Ditmarsch M, Kastelein J, Finan C
Alzheimers Res Ther
. 2024 Oct;
16(1):228.
PMID: 39415269
Background: Elevated concentrations of low-density lipoprotein cholesterol (LDL-C) are linked to dementia risk, and conversely, increased plasma concentrations of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein-A1 (Apo-A1) associate with decreased dementia...
4.
Zhang J, Cao G, Huo Y, Guarneri L, Ditmarsch M, Kastelein J, et al.
J Clin Pharmacol
. 2024 Aug;
PMID: 39158261
Obicetrapib is a selective cholesteryl ester transfer protein (CETP) inhibitor. Previous research has demonstrated similar pharmacokinetic (PK) responses to single doses of obicetrapib between Japanese and White males, but the...
5.
Khomtchouk B, Sun P, Maggio Z, Ditmarsch M, Kastelein J, Davidson M
Front Endocrinol (Lausanne)
. 2024 Jul;
15:1359780.
PMID: 38962682
Introduction: Cholesteryl ester transfer protein (CETP) inhibitors, initially developed for treating hyperlipidemia, have shown promise in reducing the risk of new-onset diabetes during clinical trials. This positions CETP inhibitors as...
6.
Dunn A, Ditmarsch M, Kastelein J, Kling D, Neild A, Davidson M, et al.
J Clin Pharmacol
. 2024 May;
64(9):1150-1164.
PMID: 38720593
Obicetrapib is a selective inhibitor of cholesteryl ester transfer protein that is currently in phase 3 of development for the treatment of dyslipidemia as adjunct therapy. The purpose of this...
7.
Nicholls S, Nelson A, Ditmarsch M, Kastelein J, Ballantyne C, Ray K, et al.
Am Heart J
. 2024 May;
274:32-45.
PMID: 38705341
Background: Obicetrapib, a novel, selective cholesteryl ester transfer protein (CETP) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), LDL particles, apolipoprotein (Apo) B, and lipoprotein(a) [Lp(a)] and increases high-density lipoprotein cholesterol (HDL-C)...
8.
Harada-Shiba M, Davdison M, Ditmarsch M, Hsieh A, Wuerdeman E, Kling D, et al.
J Atheroscler Thromb
. 2024 Apr;
31(10):1386-1397.
PMID: 38569868
Aims: Obicetrapib is a highly selective cholesteryl ester transfer protein (CETP) inhibitor shown to reduce low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB), when taken as monotherapy and in combination...
9.
Kastelein J, Hsieh A, Dicklin M, Ditmarsch M, Davidson M
Curr Atheroscler Rep
. 2023 Dec;
26(2):35-44.
PMID: 38133847
Purpose Of Review: To discuss the history of cardiovascular outcomes trials of cholesteryl ester transfer protein (CETP) inhibitors and to describe obicetrapib, a next-generation, oral, once-daily, low-dose CETP inhibitor in...
10.
Mehta N, Dangas K, Ditmarsch M, Rensen P, Dicklin M, Kastelein J
Pharmacol Res
. 2023 Oct;
197:106972.
PMID: 37898443
The main role of cholesteryl ester transfer protein (CETP) is the transfer of cholesteryl esters and triglycerides between high-density lipoprotein (HDL) particles and triglyceride-rich lipoprotein and low-density lipoprotein (LDL) particles....